Scholarlink

<p>Tanzanian girls received one to three doses of Gardasil®9 in the DoRIS randomised trial. Blood samples from one and two-dose Gardasil®9 recipients were collected at months (M)0, M7, M12, M24, and M36 for testing via an HPV Multiplex immunoassay. All participants were HPV 16, HPV 31, and HPV 58 seropositive at M36. For the one-dose group, 96.8–98.2% of girls were seropositive for HPV 11, HPV 18, and HPV 33 and 73.0-87.7% seropositive for HPV 6, HPV 45 and HPV 52. For the two-dose group, all participants were HPV 6, HPV 11, HPV 18, and HPV 33 seropositive, while 98.6% seropositive for HPV 45 and HPV 52. Geometric mean concentrations (GMCs) were higher in the two-dose group compared to the one-dose group but all GMCs in the one-dose group had plateaued by M24 and remained stable to M36. HPV vaccine immune responses in this study will continue through nine years post-vaccination. ClinicalTrials.gov ID: NCT02834637; Registration Date: 2016-06-29; <a href="https://www.clinicaltrials.gov/study/NCT02834637">https://www.clinicaltrials.gov/study/NCT02834637</a>.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Immunogenicity of one and two doses of Gardasil®9 in Tanzanian girls in the DoRIS Trial

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年12月19日

查看全文
  • Troy J. Kemp,
  • Kathy Baisley,
  • John Changalucha,
  • Jackton Indangasi,
  • Hilary Whitworth,
  • Charles J. Lacey,
  • David Mwanzalima,
  • Ramadhan Hashim,
  • Saidi Kapiga,
  • Richard J. Hayes,
  • Ligia A. Pinto,
  • Deborah Watson-Jones

摘要

Tanzanian girls received one to three doses of Gardasil®9 in the DoRIS randomised trial. Blood samples from one and two-dose Gardasil®9 recipients were collected at months (M)0, M7, M12, M24, and M36 for testing via an HPV Multiplex immunoassay. All participants were HPV 16, HPV 31, and HPV 58 seropositive at M36. For the one-dose group, 96.8–98.2% of girls were seropositive for HPV 11, HPV 18, and HPV 33 and 73.0-87.7% seropositive for HPV 6, HPV 45 and HPV 52. For the two-dose group, all participants were HPV 6, HPV 11, HPV 18, and HPV 33 seropositive, while 98.6% seropositive for HPV 45 and HPV 52. Geometric mean concentrations (GMCs) were higher in the two-dose group compared to the one-dose group but all GMCs in the one-dose group had plateaued by M24 and remained stable to M36. HPV vaccine immune responses in this study will continue through nine years post-vaccination. ClinicalTrials.gov ID: NCT02834637; Registration Date: 2016-06-29; https://www.clinicaltrials.gov/study/NCT02834637.